Pub Date : 2024-02-22DOI: 10.1016/j.clicom.2024.02.002
Amer Khojah , Madeline Schutt , Gabrielle Morgan , Ameera Bukhari , Nicolas Bensen , Aaruni Khanolkar , Lauren M. Pachman
This study investigates HLA-DR expression on activated T cells and serum neopterin levels in Juvenile Dermatomyositis (JDM) children pre- and post-treatment. Sixty-nine JDM children (less than 18 years) were included. Elevated HLA-DR+ T cells (>7 %) were observed in 19 % of untreated cases. Post-treatment, mean HLA-DR+ T cells decreased from 5.1 to 2.9 (P < 0.001), and serum neopterin levels declined from 19.3 to 9.1 nmol/L (P < 0.0001). A positive correlation between serum neopterin and HLA-DR T cell percentage was observed (r = 0.39, P = 0.01). Intravenous steroid treatment exhibited a 47.4 % improvement in HLA-DR+ T cells and a 50.5 % reduction in serum neopterin levels, in contrast to 14.8 % and 34.1 % in the oral steroid group. In conclusion, treatment, particularly with IV steroids, significantly improved HLA-DR+ T cells percentage and neopterin levels. A correlation between HLA-DR+ T cells percentage and serum neopterin was noted in untreated JDM patients.
本研究调查了幼年皮肌炎(JDM)儿童治疗前后活化 T 细胞上的 HLA-DR 表达和血清蝶呤水平。研究共纳入 69 名 JDM 儿童(18 岁以下)。在19%的未治疗病例中观察到HLA-DR+ T细胞升高(7%)。治疗后,HLA-DR+ T 细胞平均值从 5.1 降至 2.9(P <0.001),血清新蝶呤水平从 19.3 降至 9.1 nmol/L(P <0.0001)。血清蝶呤与 HLA-DR T 细胞百分比呈正相关(r = 0.39,P = 0.01)。静脉注射类固醇治疗后,HLA-DR+ T 细胞的比例提高了 47.4%,血清蝶呤水平降低了 50.5%,而口服类固醇组的比例分别为 14.8% 和 34.1%。总之,治疗(尤其是静脉注射类固醇)能明显改善 HLA-DR+ T 细胞的比例和新蝶呤水平。在未经治疗的 JDM 患者中,HLA-DR+ T 细胞百分比与血清蝶呤之间存在相关性。
{"title":"Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis","authors":"Amer Khojah , Madeline Schutt , Gabrielle Morgan , Ameera Bukhari , Nicolas Bensen , Aaruni Khanolkar , Lauren M. Pachman","doi":"10.1016/j.clicom.2024.02.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2024.02.002","url":null,"abstract":"<div><p>This study investigates HLA-DR expression on activated T cells and serum neopterin levels in Juvenile Dermatomyositis (JDM) children pre- and post-treatment. Sixty-nine JDM children (less than 18 years) were included. Elevated HLA-DR+ <em>T</em> cells (>7 %) were observed in 19 % of untreated cases. Post-treatment, mean HLA-DR+ <em>T</em> cells decreased from 5.1 to 2.9 (<em>P</em> < 0.001), and serum neopterin levels declined from 19.3 to 9.1 nmol/L (<em>P</em> < 0.0001). A positive correlation between serum neopterin and HLA-DR T cell percentage was observed (<em>r</em> = 0.39, <em>P</em> = 0.01). Intravenous steroid treatment exhibited a 47.4 % improvement in HLA-DR+ <em>T</em> cells and a 50.5 % reduction in serum neopterin levels, in contrast to 14.8 % and 34.1 % in the oral steroid group. In conclusion, treatment, particularly with IV steroids, significantly improved HLA-DR+ <em>T</em> cells percentage and neopterin levels. A correlation between HLA-DR+ <em>T</em> cells percentage and serum neopterin was noted in untreated JDM patients.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"5 ","pages":"Pages 20-25"},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000052/pdfft?md5=c452f7a7248afcb618c034100a4de811&pid=1-s2.0-S2772613424000052-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139993378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Good syndrome (GS) is a combined immunodeficiency that is associated with thymomas. The cause of the reduction in B-cells in patients with GS may be multifactorial and may include dysregulated T-cell responses. It has been proposed that tumorigenesis in a normal thymus alters thymic epithelial cell function, which leads to attenuated elimination of T-cells autoreactive to B-cells. Although the comprehensive genetic analysis of thymoma has been performed and reported in many articles, the comprehensive genetic analysis specified for GS-related thymoma has not been reported. Herein, we report comprehensive genetic analysis of a thymoma taken from a patient with GS. Oncogenesis-associated genes that may contribute to thymoma development were detected. Additionally, alteration of VCAM1, which is required in the interaction between T-cells and thymic epithelial cells, was observed. Aberrantly expressed VCAM1 in thymic epithelial cells may decrease the efficacy of negative of selection autoreactive T-cells and contribute to autoimmunity to B-cells.
古德综合征(GS)是一种与胸腺瘤相关的联合免疫缺陷病。古德综合征患者 B 细胞减少的原因可能是多因素的,其中可能包括 T 细胞反应失调。有人认为,正常胸腺中的肿瘤发生改变了胸腺上皮细胞的功能,从而导致对 B 细胞有自反应的 T 细胞的清除能力减弱。虽然已有许多文章对胸腺瘤进行了全面的基因分析和报道,但专门针对 GS 相关胸腺瘤的全面基因分析尚未见报道。在此,我们报告了对一名 GS 患者胸腺瘤的全面基因分析。我们发现了可能导致胸腺瘤发生的肿瘤发生相关基因。此外,我们还观察到T细胞与胸腺上皮细胞之间相互作用所需的VCAM1发生了改变。胸腺上皮细胞中畸形表达的VCAM1可能会降低自体反应性T细胞负向选择的功效,并导致B细胞自身免疫。
{"title":"Somatic variant profiling of a thymoma in Good syndrome","authors":"Kae Takagi , Yui Namikawa , Masayuki Nagasawa , Masahiro Mae , Yoshihiko Watanabe , Kohsuke Imai , Hirokazu Kanegane , Tomohiro Morio , Masatoshi Takagi","doi":"10.1016/j.clicom.2024.02.004","DOIUrl":"https://doi.org/10.1016/j.clicom.2024.02.004","url":null,"abstract":"<div><p>Good syndrome (GS) is a combined immunodeficiency that is associated with thymomas. The cause of the reduction in B-cells in patients with GS may be multifactorial and may include dysregulated T-cell responses. It has been proposed that tumorigenesis in a normal thymus alters thymic epithelial cell function, which leads to attenuated elimination of T-cells autoreactive to B-cells. Although the comprehensive genetic analysis of thymoma has been performed and reported in many articles, the comprehensive genetic analysis specified for GS-related thymoma has not been reported. Herein, we report comprehensive genetic analysis of a thymoma taken from a patient with GS. Oncogenesis-associated genes that may contribute to thymoma development were detected. Additionally, alteration of <em>VCAM1</em>, which is required in the interaction between T-cells and thymic epithelial cells, was observed. Aberrantly expressed VCAM1 in thymic epithelial cells may decrease the efficacy of negative of selection autoreactive T-cells and contribute to autoimmunity to B-cells.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"5 ","pages":"Pages 12-19"},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000039/pdfft?md5=cb5d7cc0913d4adf0ba1ae4f12b0b913&pid=1-s2.0-S2772613424000039-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139936671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-09DOI: 10.1016/j.clicom.2024.02.001
Emerita Quintina de Andrade Moura , Bruno Fonseca Nunes , Letícia de Oliveira Souza Bratti , Fabíola Branco Filippin Monteiro
Severe obesity is linked to a low-grade inflammatory process due to enlarged adipose tissue, resulting in elevated pro-inflammatory cytokines. Bariatric surgery induces anatomical changes, causing intestinal inflammation marked by anti-Saccharomyces cerevisiae (ASCA) antibodies. This study aimed to assess ASCA IgG/IgA levels preoperatively and 12 months post-surgery, correlating them with systemic inflammation markers (IL-6, CRP, MCP-1). Participants (BMI > 35 kg/m2) were recruited in South Brazil. Severe obesity individuals showed elevated IL-6 (p = 0.002), CRP (p<0.0001), and MCP-1 (p<0.0001) compared to lean controls. ASCA IgA was significantly higher in severe obesity (p = 0.0019). Post-surgery, ASCA IgG/IgA significantly decreased (p = 0.0046 and p<0.0001), along with IL-6, MCP-1, and CRP, confirming weight loss and reduced inflammation. Hypertrophic adipose tissue, producing pro-inflammatory cytokines, associates with increased intestinal inflammation. Bariatric surgery-induced anatomical changes contribute to long-term weight loss and reduced systemic and intestinal inflammation.
{"title":"Anti-Saccharomyces cerevisiae (ASCA) in patients with severe obesity undergoing bariatric surgery: 12-month follow-up.","authors":"Emerita Quintina de Andrade Moura , Bruno Fonseca Nunes , Letícia de Oliveira Souza Bratti , Fabíola Branco Filippin Monteiro","doi":"10.1016/j.clicom.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2024.02.001","url":null,"abstract":"<div><p>Severe obesity is linked to a low-grade inflammatory process due to enlarged adipose tissue, resulting in elevated pro-inflammatory cytokines. Bariatric surgery induces anatomical changes, causing intestinal inflammation marked by anti-Saccharomyces cerevisiae (ASCA) antibodies. This study aimed to assess ASCA IgG/IgA levels preoperatively and 12 months post-surgery, correlating them with systemic inflammation markers (IL-6, CRP, MCP-1). Participants (BMI > 35 kg/m<sup>2</sup>) were recruited in South Brazil. Severe obesity individuals showed elevated IL-6 (<em>p</em> = 0.002), CRP (<em>p</em><0.0001), and MCP-1 (<em>p</em><0.0001) compared to lean controls. ASCA IgA was significantly higher in severe obesity (<em>p</em> = 0.0019). Post-surgery, ASCA IgG/IgA significantly decreased (<em>p</em> = 0.0046 and <em>p</em><0.0001), along with IL-6, MCP-1, and CRP, confirming weight loss and reduced inflammation. Hypertrophic adipose tissue, producing pro-inflammatory cytokines, associates with increased intestinal inflammation. Bariatric surgery-induced anatomical changes contribute to long-term weight loss and reduced systemic and intestinal inflammation.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"5 ","pages":"Pages 7-11"},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000027/pdfft?md5=c057dcb1c1af28dc7e6c2a63f5eb5bcd&pid=1-s2.0-S2772613424000027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-28DOI: 10.1016/j.clicom.2024.01.001
Zein Kattih , Jonathan Moore , Dimitre G. Stefanov , Priyanka Makkar , Viera Lakticova
Background
The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.
Methods
We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.
Results
Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, p <0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, p <0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, p = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.
Conclusions
Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.
{"title":"Evaluating length of immune response to SARS-CoV2 vaccine: A cohort review of spike protein antibody titer after vaccination","authors":"Zein Kattih , Jonathan Moore , Dimitre G. Stefanov , Priyanka Makkar , Viera Lakticova","doi":"10.1016/j.clicom.2024.01.001","DOIUrl":"10.1016/j.clicom.2024.01.001","url":null,"abstract":"<div><h3>Background</h3><p>The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.</p></div><div><h3>Methods</h3><p>We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.</p></div><div><h3>Results</h3><p>Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, <em>p</em> <0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, <em>p</em> <0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, <em>p</em> = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.</p></div><div><h3>Conclusions</h3><p>Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"5 ","pages":"Pages 1-6"},"PeriodicalIF":0.0,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000015/pdfft?md5=f4633bf721f316ced2394d5c29235569&pid=1-s2.0-S2772613424000015-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-29DOI: 10.1016/j.clicom.2023.11.002
Xinyu Shao
Cholangiocarcinoma (CCA) is a group of malignant digestive system tumors with a poor overall prognosis. Late diagnosis and limited treatment are the main problems of CCA. Immunotherapy is a promising method to improve the prognosis, but the immunosuppression of CCA tumor microenvironment hinders the development and implementation of immunotherapy. Therefore, a full understanding of the complex components of CCA and its tumor immune microenvironment (TiME) can better understand the pathogenesis and drug resistance mechanism of CCA and contribute to the discovery of new immunotherapy targets. This article reviews the TiME related research on CCA, comprehensively discusses the components of the immune microenvironment of cholangiocarcinoma, and introduces the research progress of immunotherapy and immune combination therapy for CCA.
{"title":"Immune microenvironment and progress in immunotherapy of cholangiocarcinoma","authors":"Xinyu Shao","doi":"10.1016/j.clicom.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.11.002","url":null,"abstract":"<div><p>Cholangiocarcinoma (CCA) is a group of malignant digestive system tumors with a poor overall prognosis. Late diagnosis and limited treatment are the main problems of CCA. Immunotherapy is a promising method to improve the prognosis, but the immunosuppression of CCA tumor microenvironment hinders the development and implementation of immunotherapy. Therefore, a full understanding of the complex components of CCA and its tumor immune microenvironment (TiME) can better understand the pathogenesis and drug resistance mechanism of CCA and contribute to the discovery of new immunotherapy targets. This article reviews the TiME related research on CCA, comprehensively discusses the components of the immune microenvironment of cholangiocarcinoma, and introduces the research progress of immunotherapy and immune combination therapy for CCA.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 73-78"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277261342300029X/pdfft?md5=96a4cfb37b3b9075b3279e4257bd499c&pid=1-s2.0-S277261342300029X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138475163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-09DOI: 10.1016/j.clicom.2023.11.001
Katharina Mahlfleisch, Susanne Pauschenwein, Thomas Pekar
As long as there is only symptomatic treatment against thick-borne encephalitis (TBE) available, vaccination is considered the only prevention against infection.
The national vaccination recommendations prescribe a booster vaccination every 5 years after a basic vaccination has been carried out. This study deals with the question if antibodies in sufficient concentration exist or not when the last immunization had been five years ago.
The TBE titer was determined in 168 subjects using indirect ELISA and the vaccination history was collected.
The results show that 97.3 % of the participants have a sufficient titer 5 years after the last booster vaccination. The time period since the last booster and the type of the vaccine influence the antibody level the most. In conclusion, it was found that by controlling the titer, it is possible to postpone a booster vaccination, if the immunization is still sufficient.
{"title":"TBE-antibody titer study: Is a booster already necessary after 5 years?","authors":"Katharina Mahlfleisch, Susanne Pauschenwein, Thomas Pekar","doi":"10.1016/j.clicom.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.11.001","url":null,"abstract":"<div><p>As long as there is only symptomatic treatment against thick-borne encephalitis (TBE) available, vaccination is considered the only prevention against infection.</p><p>The national vaccination recommendations prescribe a booster vaccination every 5 years after a basic vaccination has been carried out. This study deals with the question if antibodies in sufficient concentration exist or not when the last immunization had been five years ago.</p><p>The TBE titer was determined in 168 subjects using indirect ELISA and the vaccination history was collected.</p><p>The results show that 97.3 % of the participants have a sufficient titer 5 years after the last booster vaccination. The time period since the last booster and the type of the vaccine influence the antibody level the most. In conclusion, it was found that by controlling the titer, it is possible to postpone a booster vaccination, if the immunization is still sufficient.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 70-72"},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613423000288/pdfft?md5=b6c5501b117cf506020a828a1da6f044&pid=1-s2.0-S2772613423000288-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92116947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-18DOI: 10.1016/j.clicom.2023.10.001
Rudrarpan Chatterjee, Amita Aggarwal
Management of Systemic lupus erythematosus is challenging due to its varied manifestations, relapses and problems associated with immunosuppressive therapy. This challenge is compounded in resource limited countries due to additional factors such as poor access to health care, limited income, out of pocket expenses for medical care and lack of financial independence of women. In the current review some of these issues have been highlighted in context of India, the most populous country of the world with current annual per capita income of around 2000 dollars.
{"title":"Challenges in the diagnosis and management of SLE in India","authors":"Rudrarpan Chatterjee, Amita Aggarwal","doi":"10.1016/j.clicom.2023.10.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.10.001","url":null,"abstract":"<div><p>Management of Systemic lupus erythematosus is challenging due to its varied manifestations, relapses and problems associated with immunosuppressive therapy. This challenge is compounded in resource limited countries due to additional factors such as poor access to health care, limited income, out of pocket expenses for medical care and lack of financial independence of women. In the current review some of these issues have been highlighted in context of India, the most populous country of the world with current annual per capita income of around 2000 dollars.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 65-69"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613423000276/pdfft?md5=29c6a1975841e985cf4103be77469c87&pid=1-s2.0-S2772613423000276-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92149049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-17DOI: 10.1016/j.clicom.2023.10.002
Manuel F. Ugarte-Gil , Graciela S. Alarcón
Systemic lupus erythematosus (SLE) affects more severely non-White populations, which is also the case in Latin America; this is the result of a combination of genetic and non-genetic factors. Among the non-genetic factors, a limited income and a low educational level impact negatively on the course and outcome of the disease; in addition, lack of access to healthcare services deprives patients from the opportunity of being managed by specialists, making the availability of the newest drugs practically impossible. Taking together, these factors reduce the probability of patients achieving good outcomes, like remission, less damage accrual, a better survival and a better health-related quality of life, among others. Several strategies have been proposed to reduce these disparities, including peer education, educational activities for patients and primary care physicians, improving healthcare networks and generating cost-effectiveness analyses.
{"title":"Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges","authors":"Manuel F. Ugarte-Gil , Graciela S. Alarcón","doi":"10.1016/j.clicom.2023.10.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.10.002","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE) affects more severely non-White populations, which is also the case in Latin America; this is the result of a combination of genetic and non-genetic factors. Among the non-genetic factors, a limited income and a low educational level impact negatively on the course and outcome of the disease; in addition, lack of access to healthcare services deprives patients from the opportunity of being managed by specialists, making the availability of the newest drugs practically impossible. Taking together, these factors reduce the probability of patients achieving good outcomes, like remission, less damage accrual, a better survival and a better health-related quality of life, among others. Several strategies have been proposed to reduce these disparities, including peer education, educational activities for patients and primary care physicians, improving healthcare networks and generating cost-effectiveness analyses.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 60-64"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49727533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.clicom.2023.08.001
G.I. Butel-Simoes , C. Kiss , K. Kong , L.B. Rosen , L.M. Hosking , S. Barnes , G.A. Jenkin , S. Megaloudis , B. Kumar , S.M. Holland , S. Ojaimi
We report a case of an adult female with disseminated tuberculosis, cytomegalovirus viraemia and haemophagocytic-lymphohistiocystosis syndrome associated with neutralizing anti- interferon gamma (IFNγ) autoantibodies demonstrated by absent IFNγ stimulated STAT1 phosphorylation in the presence of patient sera. A brief review of immunodeficiency caused by anti-IFNγ autoantibodies is also described.
{"title":"Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies – case report and brief review","authors":"G.I. Butel-Simoes , C. Kiss , K. Kong , L.B. Rosen , L.M. Hosking , S. Barnes , G.A. Jenkin , S. Megaloudis , B. Kumar , S.M. Holland , S. Ojaimi","doi":"10.1016/j.clicom.2023.08.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.08.001","url":null,"abstract":"<div><p>We report a case of an adult female with disseminated tuberculosis, cytomegalovirus viraemia and haemophagocytic-lymphohistiocystosis syndrome associated with neutralizing anti- interferon gamma (IFNγ) autoantibodies demonstrated by absent IFNγ stimulated STAT1 phosphorylation in the presence of patient sera. A brief review of immunodeficiency caused by anti-IFNγ autoantibodies is also described.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 55-59"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-23DOI: 10.1016/j.clicom.2023.08.002
Yoshiyasu Takefuji , Junya Toyokura
Goal of health policies is to protect and promote the health of communities. We examined COVID-19 policy outcomes of the 50 US states according to policymaker assumptions over time. With daily cumulative population mortality chosen as an indicator to evaluate and score outcomes of individual health policies, Hawaii had the best score and Arizona has the worst score. Our policy outcome analysis tool could identify and quantify policymakers’ faulty assumptions against COVID-19, and concludes that the more COVID-19 deaths, the greater the economic loss.
{"title":"Time-series COVID-19 policy outcome analysis of the 50U.S. states","authors":"Yoshiyasu Takefuji , Junya Toyokura","doi":"10.1016/j.clicom.2023.08.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.08.002","url":null,"abstract":"<div><p>Goal of health policies is to protect and promote the health of communities. We examined COVID-19 policy outcomes of the 50 US states according to policymaker assumptions over time. With daily cumulative population mortality chosen as an indicator to evaluate and score outcomes of individual health policies, Hawaii had the best score and Arizona has the worst score. Our policy outcome analysis tool could identify and quantify policymakers’ faulty assumptions against COVID-19, and concludes that the more COVID-19 deaths, the greater the economic loss.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 51-54"},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}